Trial Profile

Proof-of-concept study investigating AEZS 108 in pancreatic cancer.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 02 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zoptarelin doxorubicin (Primary)
Indications Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors COSCIENS Biopharma

Most Recent Events

06 Aug 2024 According to a COSCIENS Biopharma media release, the Aeterna Zentaris Inc name has been changed to COSCIENS Biopharma.
15 Dec 2010 This trial is expected to be initiated in 2011, according to an Aeterna Zentaris media release.
15 Dec 2010 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com